Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy (2015)
- Authors:
- USP affiliated authors: BONFA, ELOISA SILVA DUTRA DE OLIVEIRA - FM ; SILVA, CLOVIS ARTUR ALMEIDA DA - FM
- Unidade: FM
- DOI: 10.1016/j.vaccine.2014.12.030
- Subjects: ARTRITE REUMATOIDE (TERAPIA); VACINAS; POLISSACARÍDEOS BACTERIANOS; NECROSE
- Language: Inglês
- Imprenta:
- Source:
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
AIKAWA, Nadia E. et al. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy. Vaccine, v. 33, p. 604-609, 2015Tradução . . Disponível em: https://doi.org/10.1016/j.vaccine.2014.12.030. Acesso em: 11 fev. 2026. -
APA
Aikawa, N. E., França, I. L. A., Ribeiro, A. C., Sallum, A. M. E., Bonfá, E., & Silva, C. A. (2015). Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy. Vaccine, 33, 604-609. doi:10.1016/j.vaccine.2014.12.030 -
NLM
Aikawa NE, França ILA, Ribeiro AC, Sallum AME, Bonfá E, Silva CA. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy [Internet]. Vaccine. 2015 ; 33 604-609.[citado 2026 fev. 11 ] Available from: https://doi.org/10.1016/j.vaccine.2014.12.030 -
Vancouver
Aikawa NE, França ILA, Ribeiro AC, Sallum AME, Bonfá E, Silva CA. Short and long-term immunogenicity and safety following the 23-valent polysaccharide pneumococcal vaccine in juvenile idiopathic arthritis patients under conventional DMARDs with or without anti-TNF therapy [Internet]. Vaccine. 2015 ; 33 604-609.[citado 2026 fev. 11 ] Available from: https://doi.org/10.1016/j.vaccine.2014.12.030 - Lupus nephritis-related issues during COVID-19 pandemic quarantine
- Initial Benchmarking of the Quality of Medical Care in Childhood-Onset Systemic Lupus Erythematosus
- High rate of serious infection in juvenile idiopathic arthritis patients under biologic therapy in a real-life setting
- Latent tuberculosis infection screening in juvenile idiopathic arthritis patients preceding anti-TNF therapy in a tuberculosis high-risk country
- 23-valent polysaccharice pneumococcal vaccine in juvenile idiopathic arthritis patients: anti-tumor necrosis factor therapy role in short and long-term immunogenicity
- Therapeutic guidelines for Latin American Lupus patients methodology
- Long-term evaluation of cardiac function in juvenile idiopathic arthritis under anti-tumor necrosis factor therapy
- Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis
- Ozone decreases sperm quality in systemic lupus erythematosus patients
- Human Papilloma Virus and Chlamydia Trachomatis Infections in Rheumatoid Arthitis Under Anti-TNF Therapy
Informações sobre o DOI: 10.1016/j.vaccine.2014.12.030 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
